Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
In this report, we show that hyperglycemia-induced overproduction of superoxide by the mitochondrial electron transport chain activates the three major pathways of hyperglycemic damage found in aortic endothelial cells by inhibiting GAPDH activity. In bovine aortic endothelial cells, GAPDH antisense oligonucleotides activated each of the pathways of hyperglycemic vascular damage in cells cultured in 5 mM glucose to the same extent as that induced by culturing cells in 30 mM glucose. Hyperglycemia-induced GAPDH inhibition was found to be a consequence of poly(ADP-ribosyl)ation of GAPDH by poly(ADP-ribose) polymerase (PARP), which was activated by DNA strand breaks produced by mitochondrial superoxide overproduction. Both the hyperglycemia-induced decrease in activity of GAPDH and its poly(ADP-ribosyl)ation were prevented by overexpression of either uncoupling protein-1 (UCP-1) or manganese superoxide dismutase (MnSOD), which decrease hyperglycemia-induced superoxide. Overexpression of UCP-1 or MnSOD also prevented hyperglycemia-induced DNA strand breaks and activation of PARP. Hyperglycemia-induced activation of each of the pathways of vascular damage was abolished by blocking PARP activity with the competitive PARP inhibitors PJ34 or INO-1001. Elevated glucose increased poly(ADP-ribosyl)ation of GAPDH in WT aortae, but not in the aortae from PARP-1-deficient mice. Thus, inhibition of PARP blocks hyperglycemia-induced activation of multiple pathways of vascular damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Self-citationTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277 · cited 9×
“Lastly, incubation of BAECs with 30 mM glucose increased NF-κB activation by twofold, from 188,636 ± 13,333 AU in cells incubated in 5 mM glucose (Figure 2d, bar 1) to 379,053 ± 9,734 AU in cells incubated in 30 mM glucose (Figure 2d, bar 2), as previously described (5).”
BackgroundMethodInfluentialSelf-citationGupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
Self-citationDu, X.-L., Edelstein, D., Rossetti, L., Fantus, I. G., Goldberg, H., Ziyadeh, F., Wu, J., & Brownlee, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.22.12222 · Cited by 1,152
Self-citationPark, L., Raman, K. G., Lee, K. J., Lu, Y., Ferran, L. J., Chow, W. S., Stern, D., & Schmidt, A. M. (1998) · Nature Medicine · doi:10.1038/2012 · Cited by 1,104
Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor
Ishii, H., Jirousek, M. R., Koya, D., Takagi, C., Xia, P., Clermont, A., Bursell, S.-E., Kern, T. S., Ballas, L. M., Heath, W. F., et al. (1996) · Science · doi:10.1126/science.272.5262.728 · Cited by 1,103
Cited by
Items 101–107 of 107
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
“Supraphysiologic ROS levels activate the polyADP-ribose polymerase pathway, which inhibits, through ribosylation, the glyceraldehyde-3-phosphate dehydrogenase, causing the buildup of glycolytic intermediates and their shunting into the above-described alternative pathways, which accelerates oxidative stress in a detri…”
BackgroundFan, L., Cacicedo, J. M., & Ido, Y. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13303 · Cited by 86
Kanda, A., Noda, K., & Ishida, S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.626713 · Cited by 41
Mehta, S. L., Lin, Y., Chen, W., Yu, F., Cao, L., He, Q., Chan, P. H., & Li, P. A. (2011) · Translational Stroke Research · doi:10.1007/s12975-010-0027-3 · Cited by 36
Sugawara, T., Kano, F., & Murata, M. (2014) · Scientific Reports · doi:10.1038/srep06952 · Cited by 34
Gusdon, A. M., Chen, J., Votyakova, T. V., & Mathews, C. E. (2009) · Methods in Enzymology · doi:10.1016/s0076-6879(08)04424-8 · Cited by 16
“This leads to increased flux through the hexosamine pathway, advanced glycation end-product formation, polyol pathway flux, and increased activation of PKC isoforms—the main pathways of hyperglycemia-induced pathosis (Du et al., 2003).”
McGarrity, S., Halldórsson, H., Palsson, S., Johansson, P. I., & Rolfsson, Ó. (2016) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2016.00010 · Cited by 12
Metadata
- Authors
- Du, X., Matsumura, T., Edelstein, D., Rossetti, L., Zsengellér, Z., Szabó, C., & Brownlee, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-10-01
- Volume
- 112
- Issue
- 7
- Pages
- 1049-1057
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1996478420
- Cited by
- 832
- References
- 47
- FWCI
- 24.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.